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Abstract
Background: There is increasing evidence that oncogenic Wnt signaling directs metabolic reprogramming of
cancer cells to favor aerobic glycolysis or Warburg metabolism. In colon cancer, this reprogramming is due to
direct regulation of pyruvate dehydrogenase kinase 1 (PDK1) gene transcription. Additional metabolism genes are
sensitive to Wnt signaling and exhibit correlative expression with PDK1. Whether these genes are also regulated
at the transcriptional level, and therefore a part of a core metabolic gene program targeted by oncogenic WNT
signaling, is not known.
Results: Here, we identify monocarboxylate transporter 1 (MCT-1; encoded by SLC16A1) as a direct target gene
supporting Wnt-driven Warburg metabolism. We identify and validate Wnt response elements (WREs) in the
proximal SLC16A1 promoter and show that they mediate sensitivity to Wnt inhibition via dominant-negative LEF-1
(dnLEF-1) expression and the small molecule Wnt inhibitor XAV939. We also show that WREs function in an independent
and additive manner with c-Myc, the only other known oncogenic regulator of SLC16A1 transcription. MCT-1 can
export lactate, the byproduct of Warburg metabolism, and it is the essential transporter of pyruvate as well as a
glycolysis-targeting cancer drug, 3-bromopyruvate (3-BP). Using sulforhodamine B (SRB) assays to follow cell
proliferation, we tested a panel of colon cancer cell lines for sensitivity to 3-BP. We observe that all cell lines are
highly sensitive and that reduction of Wnt signaling by XAV939 treatment does not synergize with 3-BP, but
instead is protective and promotes rapid recovery.
Conclusions: We conclude that MCT-1 is part of a core Wnt signaling gene program for glycolysis in colon
cancer and that modulation of this program could play an important role in shaping sensitivity to drugs that
target cancer metabolism.
Keywords: Monocarboxylate transporter 1 (MCT-1), SLC16A1, Wnt signaling, Colon cancer, Metabolism,
3-Bromopyruvate, XAV939
Background
Canonical Wnt signaling regulates the fate and activ-
ities of cells through the actions of β-catenin, a
nuclear-localizing mediator that can activate the tran-
scription of Wnt target genes important in cell growth
and proliferation. A chronic increase in the cellular
levels of β-catenin can occur through oncogenic
activation of the Wnt signal transduction pathway, a
condition that leads to aberrant and elevated expres-
sion of Wnt target genes. Constitutive Wnt target gene
expression is an abnormal condition that can trans-
form cells and cause cancer, including colon cancer, a
disease defined by epithelial cell transformation within
the intestine. Colon cancer most commonly derives
from chronic activation of the canonical Wnt signaling
pathway through mutations of components in the de-
struction complex, a multi-subunit regulator in the
cytoplasm that degrades β-catenin to maintain
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appropriate, physiological levels [1–4]. Nuclear-localized
β-catenin activates target gene expression via direct bind-
ing to LEF/TCF transcription factors, a family of four
DNA binding proteins that occupy distinct gene targets
(i.e., gene programs) and direct specific phenotypes and
functions of cells. Gene programs identified to be altered
by oncogenic Wnt signaling include cell cycle progression,
epithelial-mesenchymal transition (EMT), angiogenesis,
migration, cell survival, and most recently discovered by
our group, metabolism [5–8].
Many groups have used overexpression of dominant-
negative isoforms of LEF/TCF transcription factors
(dnLEF/TCFs) in multiple contexts and model systems
to identify Wnt target genes [5, 6, 9, 10]. These shorter
forms retain the capabilities of full length LEF/TCFs to
occupy Wnt response elements (WREs) throughout the
genome, but they lack the ability to recruit β-catenin.
Interference by these dominant-negative isoforms re-
presses target gene transcription, and thus, genome-wide
expression analysis of downregulated transcription can
reveal candidate target genes and the gene programs
with which they are associated. We used this type of
analysis in colon cancer cells to discover that Wnt sig-
naling promotes tumor cell preferences for aerobic gly-
colysis/Warburg metabolism, with the Wnt target gene
pyruvate dehydrogenase kinase 1 (PDK1) playing a sig-
nificant role in this metabolic fate [8]. In that study, we
also observed additional metabolism-linked genes to be
sensitive to dnLEF/TCF expression, suggesting that
Wnt signaling coordinately regulates PDK1 within a
larger gene program. One of the additional genes af-
fected was monocarboxylate transporter 1 (SLC16A1,
encoding the protein MCT-1), a known lactate transporter
observed to be upregulated in many cancers [11, 12].
qRT-PCR analysis of xenograft tumors from a colon can-
cer cell line showed MCT-1 downregulation in the pres-
ence of dnLEF/TCFs, and ChIP-seq ENCODE data shows
TCF-4 occupancy of SLC16A1 in HCT116 colon cancer
cells [8]. These preliminary findings strongly implicate
MCT-1 as a direct Wnt target gene that might be coor-
dinately regulated with PDK1. Here, we investigate this
possibility and show that MCT-1/SLC16A1 is a direct
target gene of β-catenin-LEF/TCF complexes in colon
cancer cells.
MCT-1 is one of 14 members of the SLC16 family of
transporters [13]. While the functions of many MCT fam-
ily members remain uncharacterized, MCT-1 through
MCT-4 is confirmed proton-linked monocarboxylic acid
transporters [14]. These four family members have been
shown to transport monocarboxylates including acetoace-
tate, β-hydroxybutyrate, short chain fatty acids, pyruvate,
and lactate. In a normal setting, MCTs are necessary for
lactate efflux from highly glycolytic/hypoxic muscle fibers
during exercise, and also reabsorption or uptake of
monocarboxylates from the gut, liver, and kidney for glu-
coneogenesis or lipogenesis—activities tightly linked to
aerobic and anaerobic glycolysis [14]. MCT-1 has a rea-
sonably strong affinity for lactate compared to the other
MCTs (Km of 2.5–4.5 mM, compared to MCT-2 Km =
0.7 mM; MCT-3 Km = 6 mM; MCT-4 Km = 17–34 mM),
and it is broadly expressed, while other MCT family
members are localized to specific regions of the body at
varying levels of expression [13, 15].
While increased expression of MCT-1 in response to
the physiological stresses of exercise and physical stimu-
lation has been well defined, the molecular mechanisms
that govern its expression are still poorly understood. At
the transcriptional level, the SLC16A1 promoter contains
nuclear factor of activated T-cells (NFAT)-binding
sequences [14], but the significance of these elements is
unknown. In rat skeletal muscle tissues, PGCα (a tran-
scriptional co-activator linked to regulation of genes in-
volved in energy metabolism) has been associated with
MCT-1 upregulation in response to muscle activity [16].
However, no follow-up studies have been conducted to
determine whether the SLC16A1 promoter is subject to
direct activation. The ribonucleotide metabolite and
AMP-activated protein kinase (AMPK) activator, 5-
aminoimidazole-4-carboxamide-1-β-D-ribonucleoside
(AICAR), has been shown to upregulate or downregulate
SLC16A1 promoter activity depending on the study and
tissue context [17]. Likewise, butyrate, another metabol-
ite and energy source for the colon epithelium has been
identified to enhance transcription and transcript stabil-
ity of SLC16A1 mRNA [18], but the mechanisms and re-
sponsive genomic regions behind these effects are not
known. Finally, hypoxia was shown to upregulate MCT-
1 in human adipocytes [19], but this is a singular ex-
ample. In most tissues and cell lines studied, MCT-1 ex-
pression is not affected by hypoxia [20]. Instead, MCT-4
is considered to be the main transcriptional responder
to hypoxia as multiple, high affinity HIF response ele-
ments (HREs) have been identified in its promoter and
hypoxic expression has been demonstrated in many
tissues [20].
The observation that MCT-1 expression is increased
in cancer has led to studies focused on its regulation in
cancer cells. For example, the tumor suppressor p53 dir-
ectly binds to the MCT-1 promoter for transcription
repression, and therefore, the loss of p53 in cancer cells
enables MCT-1 mRNA production [21]. c-Myc also dir-
ectly regulates MCT-1 transcription, especially in cancer
cells where high levels of c-Myc drive metabolic path-
ways [22]. A common theme among cancer cells is the
use of elevated MCT-1 expression to support the glyco-
lytic preference of cells via its ability to export lactate.
This export minimizes the cellular stresses from acid
buildup and maintains proper intracellular pH, activities
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crucial to cancer cell survival [23]. Alternatively, a recent
study found that MCT-1 primarily exports pyruvate,
where co-expressed MCT-4 plays the dominant role in
exporting lactate [24]. This function appears to promote
glycolysis as inhibition of MCT-1 transporter activity or
downregulation of its protein levels leads to increased
oxidative phosphorylation and decreased proliferation
[24]. Taken together, no matter the precise actions of its
transporter functions, the use of MCT-1-specific inhibi-
tors has shown this transporter to be a key player in
cancer cell metabolism, survival, and proliferation, mak-
ing it a potentially important candidate target in glyco-
lytic cancer cells [25].
Recent findings highlight how MCT-1 overexpression
may be an exploitable feature for cancer therapy. Birsoy
et al. have shown that breast cancer cells expressing
MCT-1 are sensitive to 3-bromopyruvate (3-BP), a mol-
ecule that can have anti-proliferative effects by targeting
glycolytic enzymes and other metabolic pathways [26].
Like its parent molecule pyruvate, 3-BP must be trans-
ported across the plasma membrane. Birsoy et al. used
genome-wide screening to discover that 3-BP is
imported into cells strictly through MCT-1 and no other
transporter or alternative pathway. Whether this makes
MCT-1 expression the single most important biomarker
for determining tumor sensitivity to 3-BP is not yet
known, as its precise mode of action has not been de-
fined and only breast cancer cells were used in the study.
Nevertheless, there are several case reports documenting
the use of this compound in cancer patients, underscor-
ing the importance of understanding how SLC16A1 gene
expression is regulated [27, 28]. Here, we show that
MCT-1/SLC16A1 is a direct Wnt target gene coordi-
nately regulated with other genes that promote glycolysis
in colon cancer cells. We define a region in the up-
stream promoter with at least two WREs and show that
the endogenous gene is sensitive to dnLEF/TCF inhib-
ition in multiple colon cancer cell lines. We show that
transcriptional regulation by β-catenin/LEF/TCFs is sep-
arate and additive with c-Myc action. We demonstrate
that colon cancer cells are sensitive to 3-BP and that the
sensitivity tracks partially, but not completely, with the
strength of oncogenic Wnt signaling. Finally, we show
that Wnt signaling inhibitors do not synergize with 3-BP
to suppress proliferation, but instead interfere with the
anti-proliferative effects of 3-BP and provide a resistance
mechanism for colon cancer cells.
Results and Discussion
MCT-1 is regulated by Wnt signaling
Our recent discovery showing that Wnt signaling di-
rects colon cancer cells to utilize glycolysis specifically
focused on Wnt regulation of target gene pyruvate
dehydrogenase kinase 1 (PDK1), a mitochondrial kinase
that suppresses pyruvate uptake by mitochondria to
favor conversion to lactate in the cytoplasm. We uti-
lized a microarray analysis of dnLEF/TCF isoform in-
duction in the colon cancer cell line DLD-1 to reveal
novel roles of Wnt signaling in colon cancer. Gene
ontology analysis of the entire gene expression dataset
revealed that additional metabolic genes might be coor-
dinately regulated with PDK1 and might contribute to
the effect Wnt signaling has on tumor cell metabolism.
In this study, we focus on the lactate transporter
SLC16A1/MCT-1 because it lies downstream of PDK1
and glycolysis to export metabolites such as lactate, and
because it is the importer of 3-BP. We ask if MCT-1 is
directly regulated by β-catenin/LEF/TCF complexes
and if this regulation is an important consideration for
cancer therapies that target metabolism.
To validate the microarray results in DLD-1 cells and
to expand the analysis to additional colon cancer cell
lines, we used qRT-PCR to measure how SLC16A1
mRNA levels change in response to modulation of β-
catenin and LEF/TCFs. SLC16A1 mRNA was purified
from SW480 cells (Fig. 1a) and SW620 cells (Fig. 1b)
that had been stably transduced with lentivirus express-
ing physiological levels of dnLEF-1. We found that
dnLEF-1 expression reduced SLC16A1 mRNA to 50 %
(SW480) and 70 % (SW620) of parental levels, suggest-
ing that endogenous LEF/TCF/β-catenin complexes
are contributing to SLC16A1 transcription. In a separ-
ate study in SW480 cells, shRNA-mediated reduction
of β-catenin reduced SLC16A1 mRNA levels to 35 %
of control levels [29]. SLC16A1 mRNA levels were also
determined for HCT116 cells with dnLEF-1 (Fig. 1c)
and doxycycline-induced dnLEF-1 DLD-1 cells for
comparison to the microarray analysis (Fig. 1d). In
these latter two cases, we observed a reduction of SLC16A1
mRNA to approximately 60 % in each cell line.
Since there are four SLC16 family members that are
known to export lactate (MCT1-4), we asked whether
any of these were also downregulated after inhibiting
Wnt signaling. We used qRT-PCR analysis to assess the
expression of the four genes (MCT-1, MCT-2, MCT-3,
and MCT-4) in SW480, SW620, HCT116, and DLD-1
cells under the previously mentioned conditions. We
found that both SLC16A7/MCT-2 and SLC16A8/MCT-3
were undetectable in these four cell lines. SLC16A3/
MCT-4 mRNA was easily detected, but there were no
statistically significant changes in levels upon inhibition
of Wnt signaling, (albeit SLC16A3/MCT-4 was not
detected in HCT116 cells; Fig. 1a–d). We also tested
for differences at the protein level using western blot
analysis. MCT-1 levels were reduced by 20–40 % for
SW480, SW620, and HCT116 cells, similar to the re-
duction observed at the mRNA level (Fig. 1a–c). In
contrast, DLD-1 cells showed a twofold increase in


















































































































































Fig. 1 Blocking Wnt with dnLEF-1 reduces MCT-1 but not MCT-4 levels. qRT-PCR analysis was performed on RNA collected from SW480 (a) and
SW620 (b) cells stably expressing dnLEF-1. Analysis was also performed for HCT116 cells (c) 72 h after lentiviral transduction of dnLEF-1 and
DLD-1 dnLEF-1 cells (d) harvested 72 h after the addition of doxycycline. Graphs shown represent the average of three trials (+/− SEM). Whole
cell lysates from each cell line (a–d) were harvested concurrently with RNA and were probed with the antibodies shown. (*p value <0.05; **p value
< 0.01; ***p value < 0.001)
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protein level with dnLEF-1 expression, suggesting that
MCT-1 may be regulated differently in this cell line
compared to the others, possibly as unique compensa-
tory changes unfold under stable, chronic expression
of dnLEF1 (Fig. 1d). We also tested for MCT-1 expres-
sion following acute interference of Wnt signaling.
The small molecule inhibitor XAV939 acts by sup-
pressing tankyrase 1/2—poly-ADP-ribosylating en-
zymes that de-stabilize the destruction complex via
PARsylation-directed ubiquitination of axin, a key
scaffolding subunit [30]. XAV939 can therefore trigger
a rapid decrease in β-catenin levels via increased activ-
ity of the destruction complex. We treated each cell
line with XAV939 for 24 h and used qRT-PCR to
quantitate mRNA levels (Additional file 1: Figure S1).
Cell lines were treated with XAV939 for 24 and 72 h
for western blot analysis to quantitate β-catenin and
MCT-1 protein levels, respectively (Additional file 1:
Figure S1). We observed that MCT-1 expression was
significantly reduced in all four cell lines.
We next asked whether MCT-1 levels correlated with
the level of Wnt signaling. To test this, we transfected
SW480, SW620, HCT116, and DLD-1 cells with Super-
Topflash, a Wnt signaling luciferase reporter plasmid
regulated by an array of seven WREs and a minimal pro-
moter [31]. Each cell line exhibited varying levels of Wnt
signaling with SW480 cells showing the highest level of
activity by far. SW620 cells had 35-fold less activity in
comparison, and HCT116 and DLD-1 cells exhibited the
lowest levels (Fig. 2a). We hypothesized that if SLC16A1
is a direct target of Wnt signaling, the relative level of
mRNA in each of the cell lines would correlate with the
activity level of the SuperTopflash reporter. We per-
formed qRT-PCR analysis of SLC16A1 mRNA for each
cell line and normalized the results to SW480 levels
(Fig. 2b). We observed that SW620 and HCT116 cells
had lower SLC16A1 mRNA transcripts compared to the
“WntHi” SW480 cells. We also compared protein levels
using western blot analysis, normalizing protein level to
SW480 cells for comparison (Fig. 2c). MCT-1 protein
levels were lower for SW620 and HCT116 cells (50–
60 %), reflective of the relatively lower SLC16A1 mRNA
levels in these cells. DLD-1 cells differed from the cor-
relation in that even though the SuperTopflash activity
was one of the lowest, the mRNA and protein levels
were similar to WntHi SW480 cells. Since MCT-1 is
also a target of c-Myc, we used XAV939 treatment to
assess the contribution of β-catenin regulation to
MCT-1-specific activities. We developed a 14C-pyruvate
uptake assay since this capability distinguishes activity
unique to MCT-1 compared to the co-expressed MCT-
4 transporter. We used our standard XAV939 concen-
tration that partially lowers β-catenin protein levels so
as not to be lethal or affect c-Myc expression (data not
shown), and observed a decrease in the rate of pyruvate
uptake in XAV939-treated SW480 colon cancer cells
(Fig. 2d; ~2000 cpm/min reduced to ~800 cpm/min). The
60 % decrease in initial rate aligns very well with the 50 %
decrease in MCT-1 protein levels. We also evaluated
intracellular and extracellular lactate and oxidized gluta-
thione content in XAV939-treated, as well as in dnLEF-1-
expressing SW480 cells (Additional file 2: Figure S2). We
observed that extracellular (secreted) lactate levels were
significantly reduced in XAV939 and dnLEF-1 conditions,
but intracellular lactate concentrations were similar be-
tween control and treated samples. The total amount of
lactate in the media (1 μmole) was approximately 50-
fold greater than that in the cells (20 nmoles). These
data show that lactate production (glycolysis) is re-
duced when Wnt signaling is inhibited (a finding that
we have previously reported), but that the ability of the
cells to efficiently export lactate is not affected even
though MCT-1 levels are reduced. We attribute this to
the fact that MCT-4 can compensate for lactate trans-
port, an activity reported by other groups [25, 32].
Since others have shown that disruption of MCT-1
function can lead to multiple metabolic changes includ-
ing decreases in glutathione (GSH) and the emergence
of reactive oxygen species (ROS) [22], we evaluated
these two compounds. While we did not observe signifi-
cant changes in GSH content in cells (data not shown),
we did observe modest increases in ROS, albeit not quite
statistically significant (Additional file 2: Figure S2b).
Overall, these results suggest that MCT-1/SLC16A1 is reg-
ulated by Wnt/β-catenin signaling in colon cancer cells,
and with DLD-1 cells as the one exception, MCT-1/
SLC16A1 RNA, protein and activity levels correlate with
the relative levels of canonical Wnt signaling.
MCT-1 is a direct target of Wnt signaling
To ask whether Wnt/β-catenin regulation of MCT-1/
SLC16A1 expression is direct or indirect, we mined a
previously performed genome-wide ChIP-seq data set of
dnTCF-1 binding in DLD-1 cells and discovered that
TCF-1 binds to a region in the SLC16A1 locus (Fig. 3a)
[33]. This region (486 nucleotides; “ChIP peak”) of
occupancy contains two putative WREs (sequence,
Additional file 3: Figure S3). We also note that
Watanabe et al. identified this same region as a site
of β-catenin occupancy in SW480 cells [29]. To test
whether the promoter region confers active transcription
regulation in colon cancer cells, we subcloned a fragment
of the genomic locus encompassing the ChIP peak and
the transcription start site next to the luciferase open
reading frame in the plasmid pGL2b. Using “empty”
pGL2b plasmid activity as a negative control and
SuperTopflash activity as a positive control, the transi-
ent transfection assays showed that the promoter
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fragment increased reporter activity over empty vector
in each of the four surveyed lines (SW480 44-fold; SW620
98-fold; HCT116 83-fold; DLD-1 16-fold), and that it was
specifically sensitive to downregulation when dnLEF-1
was co-expressed (Fig. 3b–e, Additional file 3: Figure S3).
Two c-Myc binding sites have been previously identi-
fied within the promoter region of the gene (−624 to the
transcription start site) and shown to regulate SLC16A1
transcription [22]. Since c-Myc is a well-established Wnt
target gene, we asked whether c-Myc and LEF/TCF-β-
catenin complexes synergize mechanistically to activate
RNA polymerase II transcription of the SLC16A1 locus.
To examine this, we transfected the SLC16A1 reporter
into SW480, SW620, and DLD-1 cells and then treated
the cultures with an increasing dose of the small mol-
ecule c-Myc inhibitor 10058-F4, which prevents c-Myc-
Max interaction. The inhibitor reduced promoter activity
in all lines at similar IC50, with DLD-1 cultures showing
a modest level of decrease in sensitivity (Fig. 3f–h). A
parallel set of cultures in which dnLEF1 was expressed
to partially lower Wnt signaling were treated with the
same dose response regimen (Fig. 3f–h). While the com-
bination of Wnt and c-Myc inhibition had clear, additive
effects on transcription, there was no significant differ-
ence in the IC50 for 10058-F4 alone compared to its ef-
fects in the presence of dnLEF-1. This result suggests that
c-Myc:Max and LEF/TCF-β-catenin actions influence the



















































































































Fig. 2 Wnt signaling correlates with MCT-1 levels and activity in colon cancer cells. a Luciferase reporter activity in parental SW480, SW620,
HCT116, and DLD-1 cells shows varying levels of Wnt signaling based on SuperTopflash activity. Graph represents the average of three trials
(+/− SEM). (*p value < 0.05; **p value < 0.01; ***p value < 0.001). b qRT-PCR analysis was performed on RNA collected from parental SW480,
SW620, HCT116, and DLD-1 cells. Graph represents the average of three trials with fold change over SW480 cells (+/− SD). c Whole cell lysates from
each cell line were collected and probed with the antibodies shown. d Radiolabeled 14C pyruvate uptake assay on SW480 cells treated with
Wnt signaling inhibitor XAV939 (72 h) or vehicle (DMSO). Graph represents average of n = 4 with the shaded area showing +/− SEM (*p value
< 0.05; **p value < 0.01; ***p value < 0.001)
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Fig. 3 Wnt directly targets the MCT-1/SLC16A1 promoter for regulation. A schematic (a) depicts a region of the endogenous SLC16A1 promoter
(−1604, +1045) that was subcloned into a luciferase reporter plasmid. One regulatory region located approximately 624 nt upstream from the SLC16A1
transcription start site (+1) is occupied by dnTCF-1 and contains two putative Wnt response elements (highlighted in yellow). Previously identified
c-Myc binding sites are also represented (in purple). Transient transfection analysis of three independent experiments in SW480 (b), SW620 (c), HCT116
(d), and DLD1 (e) cells shows that the endogenous promoter fragment increases transcription, and that co-expression of dnLEF-1 reduces activity of
this promoter construct. Graphs shown represent the average of three trials (+/− SEM; *p value < 0.05; **p value < 0.01; ***p value < 0.001). Luciferase
reporter activity in SW480 (f), SW620 (g), and DLD1 (h) cells shows that treatment with the Wnt inhibitor XAV939 (10 μM) and increasing
concentrations of c-Myc inhibitor 10058-F4 decrease transcription of the SLC16A1 promoter additively, but not synergistically. A representative
graph is shown of three replicates, with calculation of the IC50 and SEM from all three replicates for each cell line in the legend
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To confirm that the putative Wnt response elements
confer transcription regulation to a heterologous pro-
moter in colon cancer cells, we subcloned the ChIP peak
next to the thymidine kinase (TK) promoter and lucifer-
ase open reading frame (Fig. 4a). Luciferase activity as-
says were performed in the presence of dnLEF-1 or Wnt
inhibitor XAV939, showing that the fragment increased
promoter activity in SW480, SW620, HCT116, and
DLD-1 colon cancer cells (Fig. 4b–e). The induction of
dnLEF-1 expression reduced luciferase expression to
near baseline in all the cell lines, and treatment with
Wnt inhibitor XAV939 also repressed reporter expres-
sion, but with more variability (Fig. 4b–e). The ChIP
peak fragment exhibited more activity in SW480 cells
and SW620 cells compared to HCT116 cells and DLD-1
cells, tracking better with the activity profile of the
SuperTopflash reporter (Fig. 2a). These results demon-
strate that SLC16A1/MCT-1 is a direct Wnt target gene
and that regulation occurs through sites within the pro-
moter locus. Therefore, MCT-1 is part of a metabolic/
glycolytic gene program directly targeted by Wnt signaling.
Wnt signaling inhibition increases colon cancer cell
resistance to 3-bromopyruvate
The importance of MCT-1 to cancer cell survival has
been well characterized in other cancers [25, 34–36],
with a recent study identifying a potential glycolysis
inhibitor that targets cells via import through MCT-1
[26]. In fact, Birsoy et al. used a genome wide siRNA
knockdown screen to discover that MCT-1 and Basigin
(the transmembrane glycoprotein responsible for an-
choring MCT-1 to the cell surface [37, 38]) are uniquely
and sufficiently capable of importing the toxic molecule
3-BP into breast cancer cells. Breast cancer cell lines
expressing high levels of MCT-1 were exquisitely sensi-
tive to treatment with 3-BP, while cell lines that did not
express MCT-1 were resistant and survived even in the
presence of the molecule. Furthermore, knockdown or
overexpression of MCT-1 in breast cancer cell lines en-
hanced or prohibited survival, respectively. Since that
study focused exclusively on breast cancer cell lines, we
asked what effect 3-BP would have on colon cancer cells.
Given that Birsoy et al. showed a direct correlation be-
tween MCT-1 levels and sensitivity to 3-BP, we asked
whether there is a correlation between the level of Wnt
signaling and 3-BP sensitivity in colon cancer cells. We
also performed the 3-BP dose-response analysis in the
presence and absence of Wnt signaling inhibitors, which
addressed a second question, namely, whether reduction
of β-catenin levels would enhance any negative effect of
3-BP on cell growth or whether it would produce com-
plex protective effects by lowering MCT-1 expression.
We first subjected cells to 48 h of vehicle or XAV939 to
lower MCT-1 protein levels, and then followed that
treatment with 96 h of increasing doses of 3-BP (Fig. 5).
We observed that colon cancer cells are as sensitive, if
not more so, than breast cancer cell lines, and that while
XAV939 treatment provided additional inhibitory effects
on growth in the presence of low concentrations of 3-
BP, it appeared to be somewhat protective at higher
doses (Fig. 5b–e). This result was further supported by
IC50 analyses which showed that XAV939 caused statisti-
cally significant increases in the 3-BP IC50 for all of the
cell lines, with the most notable differences evident in
SW480 and HCT116 cells. This data led us to ask
whether the partial protection provided by XAV939
would be evident in the cultures even after all the drugs
were removed, affecting the survival and recovery of
colon cancer cells from toxic, high doses of 3-BP.
To test this notion of survival, the four surveyed cell lines
were treated with 200, 250, or 300 3-BP—concentrations of
drug that were seven- to tenfold above the IC50. These
treatments were followed by a “wash out” and recovery
period for 5 days (Fig. 6a). In SW480 cells treated with
200 μM 3-BP, there was no significant difference in the
ability of the cells to recover in the absence or presence
of XAV939. However, at 250 μM, the cells survived sig-
nificantly better if they had been treated with XAV939,
and at 300 μM 3-BP, Wnt signaling inhibition allowed
the cells to recover where untreated cultures did not
recover at all (Fig. 6b). Similarly in SW620 cultures,
XAV939 treatment increased survival and recovery at
250 μM 3-BP, whereas the 300 μM condition had a
modest recovery (Fig. 6c). Wnt signaling-inhibited cells
survived and recovered better at every experimental
concentration of 3-BP in HCT116 cells (Fig. 6d), but
DLD-1 cells did not recover at all. The lack of DLD-1
cell recovery was unsurprising, due to this cell line hav-
ing the lowest IC50 and greatest sensitivity to 3-BP
(Figs. 5e and 6e). These data demonstrate that even
though colon cancer cells are sensitive to 3-BP, co-
treatment with Wnt signaling inhibitor XAV939, which
lowers MCT-1 expression, allows cells to resist the
toxic effects of 3-BP leading to increased survival and
enhanced recovery from a minor fraction of surviving
cells. These results reveal an important drug combin-
ation that should be avoided when trying to treat can-
cer cells with aberrant Wnt signaling and glycolytic
metabolism.
Conclusions
Here, we report that SLC16A1/MCT-1 is a direct Wnt
target gene within a program of glycolysis and angiogen-
esis that we have defined for colon cancer. We have pre-
viously shown that colon cancer cells with high levels of
oncogenic Wnt signaling (WntHi) have extremely strong
signatures of aerobic glycolysis (Warburg metabolism) in
vitro and in vivo [8]. MCT-1 upregulation in cells with







































































































































































Fig. 4 (See legend on next page.)
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(See figure on previous page.)
Fig. 4 Identification of a Wnt responsive region in the SLC16A1 promoter region. A schematic (a) representing the ChIP peak region (486 nt)
occupied by dnTCF-1, which was subcloned 5′ of the heterologous thymidine kinase (TK) core promoter and luciferase open reading frame. Luciferase
reporter activity in SW480 (b), SW620 (c), HCT116 (d), and DLD1 (e) cells shows that the ChIP peak region confers elevated transcription activity to the
heterologous TK promoter. The expression of transfected dnLEF-1, or treatment with the Wnt inhibitor XAV939 (10 μM) reduces the regulatory activity



















































































































Fig. 5 XAV939 affects colon cancer cell sensitivity to 3-bromopyruvate. a Table of IC50 values for 3-bromopyruvate in SW480, SW620, HCT116, and
DLD-1 cells. Cell cultures were pre-treated with or without XAV939 (10 μM) for 48 h prior to the addition of 3-BP. SW480 (b), SW620 (c), HCT116
(d), and DLD1 (e) cells pre-treated with the Wnt inhibitor XAV939 (10 μM) reduces survival compared to without 3-bromopyruvate treatment,
except at high concentrations. Graphs shown represent the average of three independent replicates with error bars depicting the SEM
(*p value < 0.05; **p value < 0.01; ***p value < 0.001)
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Fig. 6 (See legend on next page.)
Sprowl-Tanio et al. Cancer & Metabolism  (2016) 4:20 Page 11 of 18
oncogenic Wnt signaling supports their adoption of a
glycolytic phenotype, likely through lactate efflux to
maintain intracellular pH, but also through its unique
ability to transport pyruvate which can influence the bal-
ance of glycolysis and oxidative phosphorylation [24].
Indeed, we observed that inhibition of β-catenin had
marked effects on pyruvate transport (Fig. 2d). We find
that colon cancer cells express one other monocarboxyl-
ate transporter (MCT-4) with high capacity for lactate,
albeit with lower affinity. Mass spectrometry detection
of intracellular and extracellular lactate indicates that
lactate levels inside cells remain stable and low, even
when MCT-1 expression is reduced (Additional file 2:
Figure S2). We attribute the compensatory action to
MCT-4 such that together, MCT-1 and MCT-4 provide
sensitive and responsive maintenance of pH homeostasis
for the intracellular environment. Current studies to
examine the unique contributions of MCT-1 to the
metabolic profile of colon cancer cells and tumors are
ongoing. While previous studies have shown that c-Myc
can activate SLC16A1 transcription (as c-Myc:Max het-
erodimers), we find that this action works with LEF/
TCF-β-catenin complexes in an additive manner. That
is, the molecular actions of c-Myc:Max are not function-
ally dependent or synergistic with LEF/TCF-β-catenin.
Since c-Myc is itself a Wnt target gene, SLC16A1 tran-
scription is targeted both indirectly (c-Myc) and directly
(LEF/TCF-β-catenin complexes) by the oncogenic Wnt
pathway, perhaps underscoring the importance of MCT-
1 function in colon tumors. To further test for a correl-
ation between Wnt signaling and MCT-1, we performed
a limited case study of primary human colon tumors
from four patients and used immunohistochemical stain-
ing to compare the expression patterns of β-catenin and
MCT-1. We observed a striking correlation when there
was obvious nuclear localization of β-catenin (Fig. 7a).
However, we also note that MCT-1 expression exhibits a
broad staining distribution in the epithelial portion of
tumors (not in the stroma), but with heterogeneous pat-
terns that reflect β-catenin staining localization (and
therefore elevated Wnt signaling), as well as other pat-
terns that do not necessarily correlate with β-catenin
(see additional examples in Additional file 4: Figure S4).
It is likely that additional signals and microenvironmen-
tal conditions exert important influence on SLC16A1/
MCT-1 expression, influences that are also important to
define now that we know MCT-1 is the single most
important transporter of the candidate cancer drug 3-
bromopyruvate.
Targeting metabolism is a promising avenue for treat-
ment of colon cancer, and 3-bromopyruvate is a toxic
small molecule that targets multiple enzymes in glycoly-
sis, particularly in cells exhibiting high rates of Warburg
metabolism [26, 39]. High levels of glycolysis result in
the accumulation of metabolic products that alter intra-
cellular pH, generating high levels of H+ that unless
eliminated, would cause cell death. MCT proteins such
as MCT-1 and MCT-4 can rid cancer cells of H+ via
proton-coupled export of lactate, the “waste” end prod-
uct of glycolysis, providing an important survival func-
tion for cancer cells. Also, MCT-1 is a pyruvate
transporter, and as such can modulate the relative levels
of glycolysis and oxidative phosphorylation. Thus, cells
that have high levels of glycolytic activity tend to exhibit
strong expression of MCT-1 and/or MCT-4 [40]. Studies
with breast cancer cell lines show that 3-BP enters cells
specifically and only through MCT-1. Signaling pathways
and microenvironmental influences that regulate MCT-1
expression are therefore extremely important consider-
ations for determining tumor sensitivities to this prom-
ising anti-cancer agent [35].
The discovery that Wnt signaling drives oncogenesis
in many tumor types (including over 80 % of colorectal
cancers) has inspired the development of small molecule
inhibitors to target the pathway. Even though there is
concern that Wnt signaling is necessary for stem cell
compartments in normal tissues and therefore inhibitors
will be deleterious and not tolerated, therapeutic win-
dows have been demonstrated in animal experiments
where Wnt-driven oncogenesis has been suppressed
without general toxicity [41]. Thus, the therapeutic rele-
vance of inhibiting the Wnt pathway in cancer remains,
and multiple drugs that inhibit Wnt signaling are show-
ing promise for clinical application (e.g., inhibitors of
Wnt secretion, tankyrase 1/2 inhibitors, and inhibitors
of β-catenin interactions) [42]. Here, we used XAV939 (a
tankyrase inhibitor that promotes axin stabilization) to
reduce Wnt signaling in the presence or absence of a
metabolic inhibitor. XAV939, as well as a similar-acting
compound called IWR-1, inhibits Wnt signaling down-
stream of ligand-receptor interaction at the level of the
destruction complex. The destruction complex is a large,
(See figure on previous page.)
Fig. 6 XAV939 promotes colon cancer cell recovery from 3-bromopyruvate. a Experimental workflow for colorimetric-based survival curve assay.
Individual cell lines were seeded on day 0 and treated after 24 h (day 1) with 200, 250, or 300 μM 3-bromopyruvate +/− Wnt signaling inhibitor
XAV939 (10 μM) until day 5. On day 5 treatments were “washed out” and replaced with control medium. Cells were fixed on days 5–10 post
seeding to observe recovery over time. SW480 (b), HCT116 (d) cells treated with the Wnt signaling inhibitor XAV939 (10 μM) survived and
recovered compared to without treatment of 3-bromopyruvate. SW620 (c) cells recovered similarly +/− XAV939 treatment, and DLD1 cells (e) did not
recover. Graphs shown represent the average of three independent replicates (+/− SEM) (*p value < 0.05; **p value < 0.01; ***p value < 0.001)
Sprowl-Tanio et al. Cancer & Metabolism  (2016) 4:20 Page 12 of 18
-catenin MCT-1a
b
Fig. 7 (See legend on next page.)
Sprowl-Tanio et al. Cancer & Metabolism  (2016) 4:20 Page 13 of 18
multi-subunit complex in the cytoplasm that targets β-
catenin for degradation [43]. XAV939 treatment acts to
stabilize the destruction complex and promote β-catenin
degradation. Both XAV939 and IWR-1 are currently in
pre-clinical development [42], though the low potency of
these specific molecules has prompted the development
of second generation drugs that target axin stabilization.
For example, tankyrase inhibitors such as GM244-LM,
a XAV939 analogue, and G007-LK are in the pipeline,
both with greater specificity to tankyrase 1 and 2 [42,
44]. Interestingly, XAV939 increases sensitivity to che-
motherapeutic drugs 5-fluorouracil and cisplatin in
SW480 and SW620 cells, suggesting that Wnt inhibi-
tors might be good candidates for combination with
standard-of-care therapies [45], or possibly with new
therapies that target metabolism such as 3-BP. Our
work adds a note of caution to this latter idea as we
show here that Wnt signaling is pivotal in upregulat-
ing the expression of MCT-1, the very transporter that
3-BP needs to gain access to cells.
Whether the level of Wnt signaling is the single most
important indicator for cell sensitivity to 3-BP depends
on understanding whether alternative modes exist for
regulation of MCT-1 and whether the toxic activities of
3-BP target different processes inside cells. Our studies
show that MCT-1 mRNA and protein levels largely cor-
related with Wnt signaling but that DLD-1 cells were an
exception. DLD-1 cells are the most sensitive to 3-BP
(IC50 = 23 μm), even though this cell line has low Wnt
signaling. In fact, these cells have relatively high levels of
MCT-1 mRNA and protein, similar to those in the
WntHi SW480 cells (Fig. 2). There were also differences
in the way the SLC16A1 promoter responded to c-Myc
and dnLEF-1 inhibition. The promoter had a slightly
lower sensitivity to the c-Myc inhibitor (IC50 of 34 μM
compared to SW480 cells (18 μM) and SW620 cells
(10 μM)). To note, dnLEF-1 expression only made a no-
ticeable difference at the lowest concentration of c-Myc
inhibitor (Fig. 3), suggesting that there are relative differ-
ences in the way β-catenin/LEF and c-Myc contribute to
promoter activity in DLD-1 cells. In general, c-Myc reg-
ulates two different kinetic steps of transcription at pro-
moters: an early step of polymerase recruitment and
initiation complex assembly, and pause-release at a later,
downstream step [46]. Perhaps, the kinetics and contri-
butions of these steps differ between DLD-1 and other
cells. Whatever the mechanistic differences at the
promoter, MCT-1 expression and by implication, 3-BP
import potential, may have more to do with c-Myc than
Wnt signaling in DLD-1 cells.
Finally, our data highlight interesting patterns of colon
cancer cell growth when Wnt signaling inhibitors are
combined with 3-BP treatment. Our hypothesis was that
if MCT-1 is a target of Wnt signaling, and if MCT-1
transport is the mechanism by which 3-BP gains access
to colon cancer cells, then inhibition of Wnt signaling
should reduce sensitivity to 3-BP. We confirmed this hy-
pothesis in the four cell lines, with the most obvious and
notable effects emerging in SW480 and HCT116 cells.
In these two cell lines, the IC50 for 3-BP inhibition was
significantly shifted to higher concentrations when
XAV939 was included in the cultures. Interestingly, even
using concentrations of 3-BP that were so high as to re-
duce cell numbers to below the point of detection
(300 μM), we observed that XAV939 co-treatment
allowed cultures to recover better and faster after the
drugs were washed out. It is particularly notable that
even though XAV939 had only a small, albeit significant
effect on protection in SW620 cells (Fig. 5b, d), its pro-
tective effects were more noticeable after the drug was
removed (Fig. 6c). Meaning, even though there was no
detectable live cells after 5 days of 3-BP treatment,
XAV939-treated cultures retained a small number of vi-
able cells which then recovered better and faster over
the next 5 days. We speculate that XAV939 triggers
adaptations that confer faster recovery and cell cycle
progression. This possibility points to the caveats that
can arise when two classes of drugs are combined. These
data also suggest that the heterogeneous patterns of
Wnt signaling that have been observed in primary
human colon cancer, and within the tumor microenvir-




Colon cancer cell lines were grown under the following
conditions: SW480 and SW620 were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Fisher SH3008102)
supplemented with 10 % fetal bovine serum (FBS; Atlas
FP-0500-A) and 2 mM glutamine (Fisher MT-25-005-CI).
HCT116 and DLD-1 were cultured in RPMI-1640
medium (Fisher MT15040CM) supplemented with
10 % FBS and 2 mM glutamine. Doxycycline-inducible
(See figure on previous page.)
Fig. 7 Wnt signaling influences cancer metabolism through regulation of SLC16A1/MCT-1 expression. a Immunohistochemical staining of human
colon tumor samples (β-catenin and MCT-1) shows correlations between nuclear β-catenin and high levels of MCT-1. Middle and bottom rows
show higher power images of boxed portions in the row above. b Model of a colorectal tumor with Wnt signaling regulating cancer metabolism
through target genes including SLC16A1/MCT-1 expression. Examples of Wnt signaling and metabolic inhibitors currently under clinical development
shown in boxed regions
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DLD-1 cells were created by transfecting Tet-inducible
dnLEF-1N into DLD-1 TR7 cells (a generous gift from
M. van de Wetering and H. Clevers) as previously de-
scribed [8]. The induction of dnLEF-1 was achieved
through addition of 0.01 μg/ml doxycycline to the
media. Lentiviral constructs were cloned via Cold
Fusion (System Biosciences) by inserting the coding se-
quence for flag-tagged dnLEF-1N into pCDH lentivector
(System Biosciences; SBI CD533A-2). See “Luciferase re-
porter plasmid cloning” section for details regarding TK
and SLC16A1 reporters.
Lentiviral preparation and infection
Lentiviruses were prepared using System Biosciences
lentivirus technology. Two-hundred ninety-three TN
cells (System Biosciences (SBI) LV900A-1) were seeded
in 150-mm plates at 7.5 × 106 cells per plate with 20 mL
DMEM without antibiotics for 24 h. Cells were then
transfected with 22.5 μg pPACKH1 HIV packaging mix
(SBI LV500A-1) and 4.5 μg of pCDH lentiviral vector
using BioT transfection reagent. Viral supernatant was
collected 48 and 72 h post-transfection. After centrifuga-
tion for 15 min at 3000×g to remove debris, 1× PEG-it
(SBI LV810A-1) was added to precipitate virus. After in-
cubation at 4 °C for at least 16 h, centrifugation (30 min
at 1500×g) was used to collect viral particles. Virus was
resuspended in a small volume (300–500 μL) 1× phos-
phate buffered saline (PBS) and titered using the Global
UltraRapid Lentiviral Titer Kit (SBI LV961A-1). Trans-
duction of target cells was performed according to
manufacturer’s protocol (SBI). Briefly, cells were seeded
at 1.0 × 105 cells per 12-well or 2.5 × 105 cells per six-well
plate. After 24 h, cells were treated with fresh media, 1×
TransDux (SBI LV850A-1), and lentivirus at a multiplicity
of infection (MOI) of 10. MOI was determined using pre-
viously published methods. Infected cells were collected
for subsequent assays after 72 h.
Real-time PCR
Total RNA was isolated with Trizol from SW480 and
SW620 expressing dnLEF-1. HCT116 cells were lentivi-
rally transduced with dnLEF-1, and total RNA was iso-
lated with Trizol 72 h post transduction. Total RNA was
isolated with Trizol from DLD-1 cells after treatment
with doxycycline for 72 h. A total of 2 μg of RNA were
reverse transcribed using random primers according to
the high capacity cDNA reverse transcription kit (Invi-
trogen 4374966). Real-time quantitative PCR (qRT-PCR)
was performed with Maxima SYBR Green/ROX qPCR
Master Mix (Fisher K0223). Relative change in gene ex-
pression was calculated using the ΔΔCt method using
GAPDH expression for normalization. Statistical evalu-
ation was performed by Student’s unpaired t test. p < 0.05
was considered statistically significant.
Primer pairs used for real-time PCR analysis include
human GAPDH (5′-TCGACAGTCAGCCGCATCTTC
TT-3′) and reverse (5′-GCGCCCAATACGACCAAATC
C-3′), human MCT-1 forward (5′-CACCGTACAGCAA
CTATACG-3′) and reverse (5′-CAATGGTCGCCTCTT
GTAGA-3′), human MCT-2 forward (5′-GGCTGGTTC
CCTCATGAGAC-3′) and reverse (5′-GCTACCACAAT
AGCCCCAC-3′), human MCT-3 forward (5′-TCGTG
GGCTTCGTGGACAT-3′) and reverse (5′-GCACAAC
GCAGGCAGCAGTT-3′), human MCT-4 forward (5′-A
TTGGCCTGGTGCTGCTGATG-3′) and reverse (5′-C
GAGTCTGCAGGAGGCTTGTG-3′).
Western blot analysis
Cell lysates were prepared according to previously pub-
lished methods [8] and 40 μg of lysate were analyzed
by Western blot using the following antibodies: Lamin
A/C (1:1000 Cell Signaling 2032), β-Tubulin (1:1000
GeneTex GTX107175), MCT-1 (1:1000 Santa Cruz SC-
50324), β-catenin (1:1000 Cell Signaling #8480), and
secondary antibody (1:5000 anti-rabbit IgG-horseradish
peroxidase; Genesee 84-852). Blots were exposed to
SuperSignal West Dura (Fisher PIA34075) and imaged
on the Syngene GBox XL1.4 Imaging System.
14C Pyruvate uptake assay
SW480 cells were seeded at 4.0 × 104 per 24-well 24 h
prior to treatment. Cells were treated with 10 μM
XAV939 or control DMSO in phenol-free DMEM. After
72 h of treatment, the 14C pyruvate-labeled uptake assay
was performed at room temperature. Cells were first
rinsed with room temperature HBSS (pH 6 with MES)
and then incubated with 1 mM sodium pyruvate in
HBSS with or without 0.5 μCi/mL 14C Pyruvate (Perkin
Elmer NEC256050UC) for 0, 2, 15, 30, or 60 min. Fol-
lowing the incubation, the plates were placed on ice
blocks to stop transport and rinsed with cold HBSS (pH
6 with MES). A cold stop solution of 2.2 mM HEPES
and 0.21 M KCL was added to each well followed by
cold 0.3 N NaOH with 0.1 % Triton-X. Plates were incu-
bated at room temperature overnight prior to perform-
ing scintillation counts to collect CPM numbers for each
sample. CPM numbers were normalized by protein via
Bradford assay (Bio-Rad Quick Start 1× Bradford Dye
5000205). Statistical evaluation was performed by Stu-
dent’s unpaired two tailed t test with p < 0.05 considered
statistically significant.
Luciferase reporter plasmid cloning
To create a luciferase reporter plasmid driven by the hu-
man SLC16A1 or herpes virus thymidine kinase pro-
moter, 5′ flanking sequences of the primers (see below;
lower case) were designed for complementarity to the
pGL2 or tkLUC vector backbone for use with a Cold
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Fusion cloning schema (Cold Fusion Cloning; System Bio-
sciences). Human placental DNA was used as template for
PCR amplification of the SLC16A1 gene core promoter
using Pfu Turbo polymerase. The PCR fragment and
SmaI-digested pGL2 vector was purified following the
manufacturer’s protocol (GeneJET Gel Extraction Kit,
Fisher K0691), and ligations were performed with an in-
sert/plasmid ratio of 1:2 with Cold Fusion reagents.
Clones were verified by sequencing. The following PCR
primers were used:
Forward primer (−1604), upper case sequence is gen-
omic, and lower case sequence is complementary to
pGL2): 5′-gag cta aca taa ccc TCC TGG GAT TCA TCT
TAT TT-3′
Reverse primer (+1045), upper case sequence is gen-
omic, and lower case sequence is complementary to
pGL2): 5′-agc tcg gta cct ccc tAT CCT CCA GAT TTC
TCT CA-3′
The following PCR primer sequences were used to
amplify a region identified as occupied by TCF-1, for
cloning 5′ of the heterologous herpes virus tk promoter
(tkLUC):
Primers designed for amplification and insertion into a
plasmid backbone containing a minimal Herpes Virus
thymidine kinase reporter (at BamHI):
ChIP Peak (486 nt; chromosome 1 113499604-
113500089)
Forward primer (upper case sequence is genomic, and
lower case is complementary to tkLUC):
5′-atc tta tca tgt ctg TCC TGG CAA GCA GCA-3′
Reverse primer (upper case sequence is genomic, and
lower case is complementary to tkLUC):
5′-ctc gga ccc cgg atc GTG GGT TGG GGT GTG-3′
Luciferase assay
Cells were seeded at 2.5 × 105 per six-well 24 h prior to
transfection. Each well was transfected with 0.5 μg M50
Super 8×TOPflash (a gift from Dr. RT Moon; Addgene
plasmid 12456), TK, or SLC16A1 luciferase reporters
and 0.1 μg thymidine kinase β-galactosidase plasmid
using BioT transfection reagent (Bioland Scientific B01-
02). Cells were transfected with 0.01 μg/mL dnLEF-1
and/or treated with 10 μM XAV939 at the time of
reporter transfection where indicated. Cells were
harvested 24-h post transfection and assayed for lucif-
erase activity and β-galactosidase activity (used for
normalization). Statistical evaluation was performed by
Student’s unpaired t test. p < 0.05 was considered statis-
tically significant.
Sulforhodamine B (SRB) cell growth assay
For 3-bromopyruvate dose-response curves, SW480 and
SW620 cells were seeded in 96-well plates at 5000 cells
per well with eight replicates for each condition.
HCT116 and DLD-1 cells were seeded in 96-well plates
at 2500 cells per well, optimized to obtain confluent cul-
tures around day 7 of each experiment, with eight repli-
cates for each condition. Twenty-four hours after
seeding, cells were pre-treated with 10 μM XAV939 for
48 h, followed by 3-BPr for a period of 96 h. Cells were
then fixed 96 h after 3-BPr treatment and stained with
sulforhodamine B according to published protocols [47]
with optical density readings performed at 492 nm.
For drug wash-out survival assays, cells were seeded in
96-well plates at 5000 cells per well with eight replicates
for each condition. Twenty-four hours after seeding,
cells were treated for a period of 96 h (4 days). On day
5, media containing treatment was removed and re-
placed with media containing no treatment to begin
“recovery” period. Cells were fixed on days 5–10, with
days 0–5 considered post wash-out, and stained accord-
ing to published protocols [47]. Optical density read-
ings were performed at 492 nm.
Statistical evaluation was performed by Student’s un-
paired t test. p < 0.05 was considered statistically significant.
Immunohistochemistry
For MCT-1 and β-catenin staining in human colon
tumor samples, following pressure cooker antigen re-
trieval in citrate buffer, adjacent sections were blocked
in 3 % H2O2, goat serum, and avidin-biotin blocking re-
agent (Vector Labs). Sections were incubated with pri-
mary antibody solutions: anti-MCT-1 (Santa Cruz SC-
50324, 1:500) or anti-β-catenin (BD Biosciences 610154,
1:500), followed by biotinylated secondary antibodies
and visualization using a peroxidase-conjugated avidin-
based Vectastain protocol. Slides were then counter-
stained with hematoxylin and mounted.
Additional files
Additional file 1: Figure S1. Blocking Wnt with XAV939 reduces MCT-1
levels. qRT-PCR analysis was performed on RNA collected from SW480
(A), SW620 (B) HCT116 (C) and DLD-1 (D) cells treated with XAV939
(10 μM) for 24 h. Graphs shown represent the average of three trials
(+/− SEM). Whole cell lysates from each cell line (A-D) were harvested
72 h (for MCT-1) and 24 h (for β-catenin) after XAV939 treatment
(10 μM) and were probed with the antibodies shown. (*p value < 0.05;
**p value < 0.01; ***p value < 0.001). (PDF 678 kb)
Additional file 2: Figure S2. Disruption of oncogenic signaling leads to
decreased lactate production and increased GSSG levels. SW480 cell
cultures treated with vehicle (DMSO) or XAV inhibitor, or established cell
lines transfected with either empty vector (mock) or a dnLEF-1 construct,
were grown to 80 % confluency in 10-cm tissue culture plates in 10 %
FBS supplemented DMEM medium. Cells and conditioned media were
collected for metabolite extraction as follows. Briefly, cells were harvested
from plates by trypsinization, counted and 4–5 replicate aliquots of 10e6
cells/sample prepared. Cells or media were collected by centrifugation at
1200×g for 5 min, rinsed with phosphate buffered saline, and extracted
with 75 % ethanol/10 mM HEPES pH 7.4 buffer (final) at 80 °C for 5 min.
Lysates were cleared by centrifugation at 12,000×g for 10 min at 4 °C.
Supernatants were lyophilized, resuspended in 10 mM ammonium
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formate buffer, and cleared supernatant transferred to low volume mass
spectrometry sample vials. Panel (A) lactic acid and panel (B) oxidized
glutathione (GSSG) were quantitated by UPLC ESI MSMS on a Waters
Quattro Premier XE instrument using ESI− and ESI+ ion modes, respectively.
Analyte concentrations of lactic acid and GSSG were calculated from 8-
point calibration standard curves in the range of 0.1–300 μM, quadratic fit,
r2 > 0.98. Data are shown for intracellular and media concentrations as
scatter plots with means ± SEM, n = 4–5. **p < 0.01, ***p < 0.001. Instrument
settings for lactic acid: UPLC gradient—solvent A: water + 0.1 % formic acid,
solvent B: 50 % acetonitrile: 50 % isopropanol + 0.1 % formic acid. Initial
10 % B→90 % B in 3 min, hold 90 % B for 1 min. MS tuning settings: SRM
89→47, CV 20, CE 50, RT 0.45 min. Instrument settings for GSSG: UPLC
gradient—solvent A: water + 0.2 % acetic acid, B acetonitrile + 0.2 %
acetic acid. Initial 10 % B→90 % B in 3 min, hold 1 min. MS tuning
settings, SRM 613→231, CV 20, CE 30, RT 0.58 min. Column: Waters
UPLC C18 BEH column, 1.7 μM, 2.1 × 50 mm. (PDF 305 kb)
Additional file 3: Figure S3. SLC16A1 transcription is directly regulated
by LEF/TCFs and Wnt signaling. (A) Schematic of one regulatory region
located approximately 624 nt upstream from the SLC16A1 transcription
start site (+1) is occupied by dnTCF-1 and contains two putative Wnt
response elements (WREs). Genomic location and sequence show
putative WREs highlighted in red. (B) SuperTopflash reporter serves
as a positive control for luciferase activity assays in parental SW480,
SW620, HCT116, and DLD-1 cells. The SuperTopflash reporter is significantly
sensitive to repression by dnLEF-1. (PDF 318 kb)
Additional file 4: Figure S4. MCT-1 and β-catenin staining in human
colon tumor samples. Immunohistochemical staining of four human
colon tumor samples (β-catenin and MCT-1) shows heterogeneous
patterns for both β-catenin and MCT-1. β-catenin and MCT-1 were
stained in adjacent tumor slices. Images shown at ×20 magnification.
(PDF 31 kb)
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